Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK
1. Centers for Medicare & Medicaid Services (CMS). Medicare Provider Analysis and Review (MedPAR) File. Fiscal Year 2023. 2. Vasan V, et al. J Stroke Cerebrovasc Dis. 2023;32(9):107295. 3. Arnold M, et al. PLoS One. 2016;11(2):e0148424. 4. Fraser C, et al. Neuron. 2002;34(5):831–840. 5. Suntrup-Krueger S, et al. Crit Care. 2023;27(1):383. 6. Youssef G, et al. Al-Azhar Assiut Med J. 2015;13(1):68–72. 7. Suntrup-Krueger S, et al. Crit Care. 2025;May 17:e00613. 8. Suntrup-Krueger et al. Crit Care. 2023;27(1):383.
Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients. Phagenyx Safety Information.
Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.
Federal law in the US restricts this device to sale by or on the order of a physician. Phagenyx Safety Information. The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.’